• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

SB228357 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755511

SB228357 is a selective and potent 5-HT2C/2B receptor antagonist (pKi: 6.9, 8.0, and 9.0 for 5-HT2A, 5-HT2B and 5-HT2C, respectively). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
SB228357, Inhibitor
Full Product Name
SB228357
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
431.38
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C22H17F4N3O2
SMILES
O=C(N1CCC2=C1C=C(C(F)(F)F)C(OC)=C2)NC3=CC(C4=CC=CN=C4)=CC(F)=C3
CAS Number
181629-93-6
Target & IC50
5-HT2A Receptor: ic50 6.9 (pki)
5-HT2C Receptor: ic50 9 (pki)
5-HT2B Receptor: ic50 8 (pki)
In Vitro
SB228357 (0-10mg/kg; p.o.; for 90 minutes; male Sprague Dawley rats) treatment,obviously reverses Haloperidol-induced catalepsy [2].

Structure of SB228357, inhibitor

SB228357 Inhibitor – Cat# MBS5755511

Product References and Citations for SB228357, inhibitor

Bromidge SM, et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
Bromidge SM, et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
Reavill C, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
Reavill C, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.

Other Notes

Small volumes of SB228357, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for SB228357 purchase

MBS5755511 is an inhibitor targeting SB228357.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000